biOasis Technologies Inc. (biOasis) is an early stage Canada-based biopharmaceutical company focused on research, development and commercialization of technologies and products intended for diagnosis and treatment of central nervous system (CNS) diseases, including brain cancer. The Company was engaged in the development of a vector, Transcend and Transcend pep for the transport of therapeutic agents across the blood brain barrier (BBB). Transcend Platform exploits the blood-brain barrier (BBB) penetrating properties of a recombinant soluble human protein known as melanotransferrin (also referred to as MTf or p97). The Company reported that Transcend pep effectively delivers siRNA across the blood-brain barrier and into brain cells. The Company also initiated studies to assess the therapeutic potential of BT2111 for the treatment of brain metastases of HER2+ breast cancer.